Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder

Journal of the American Academy of Dermatology

Volumn 47, Issue 5, 2002, Pages 785-788

  Salopek, Thomas G ^a   Logsetty, Sarvesh ^a   Tredget, Edward E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; RITUXIMAB;

ADULT; ARTICLE; BRONCHOSPASM; CASE REPORT; CHILL; DISEASE COURSE; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; FEVER; HUMAN; IMMUNOTHERAPY; NAUSEA; PATHOGENESIS; PEMPHIGUS; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PRIORITY JOURNAL; PRURITUS; REMISSION; SEPSIS; SKIN BIOPSY; SKIN DISEASE; TREATMENT OUTCOME;

EID: 0036827616     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.126273     Document Type: Article

References (16)

1. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992;90:919-26.
2. Moncada B, Kettelsen S, Hernandez-Moctezuma JL, Ramirez F. Neonatal pemphigus vulgaris: Role of passively transferred pemphigus antibodies. Br J Dermatol 1982;106:465-7.
3. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982;306:1189-96.
4. Lin MS, Swartz SJ, Lopez A, Ding X, Fernandez-Vina MA, Stastny P, et al. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J Clin Invest 1997;99:31-40.
5. Hertl M, Riechers R. Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris. J Dermatol 1999;26:748-52.
6. Juhasz I, Lazarus GS, Murphy GF, Shih IM, Herlyn M. Development of pemphigus vulgaris-like lesions in severe combined immunodeficiency disease mice reconstituted with lymphocytes from patients. J Clin Invest 1993;92:2401-7.
7. Hertl M. Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int Arch Allergy Immunol 2000;122:91-100.
8. Liu YJ, Banchereau J. Regulation of B-cell commitment to plasma cells or to memory B cells. Semin Immunol 1997;9:235-40.
9. Nishifuji K, Amagai M, Kuwana M, Iwasaki T, Nishikawa T. Detection of antigen-specific B-cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: Requirement of Tcell collaboration for autoantibody production. J Invest Dermatol 2000;114:88-94.
10. Grillo-Lopez AJ. Rituximab: An insider's historical perspective. Semin Oncol 2000;27(Suppl 12):9-16.
11. Duchosal MA. B-cell development and differentiation. Semin Hematol 1997;34:2-12.
12. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000;27(6 Suppl 12):79-85.
13. Terstappen LW, Johnsen S, Segers-Nolten IM, Loken MR. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 1990;76:1739-47.
14. Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000;133:275-9.
15. Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001;66:142-4.
16. Slifka MK, Ahmed R. Long-lived plasma cells: A mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998;10:252-8.